Want to see AU:ALC full AI Analyst Report?
ALC Stock Chart & Stats
AU$0.10
>-AU$0.01(-3.37%)
At close: 4:00 PM EDT
AU$0.10
>-AU$0.01(-3.37%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.15
Previous CloseN/A
Volume2.06M
Average Volume (3M)1.28M
Market Cap
AU$134.98M
Enterprise ValueAU$121.20
Total Cash (Recent Filing)AU$20.64M
Total Debt (Recent Filing)AU$814.00K
Price to Earnings (P/E)61.8
Beta0.86
Next Earnings
Feb 25, 2027EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,349,805,200
10 Day Avg. Volume709,667
30 Day Avg. Volume1,282,854
Financial Highlights & Ratios
PEG Ratio1.48
Price to Book (P/B)1.55
Price to Sales (P/S)2.73
P/FCF Ratio21.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.15Price Target Upside47.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$53.97M
Bulls Say, Bears Say
Bulls Say
Recurring Healthcare Software ModelRecurring software, support and maintenance revenue can improve customer retention and revenue visibility across the healthcare provider base. Multi-year contracts and expansion into additional sites or modules may support durable relationships and a compounding installed-base opportunity.
Improving Revenue And EarningsThe return to positive earnings alongside renewed revenue growth indicates a meaningful improvement from the prior loss-making period. If maintained, this combination can strengthen internal funding capacity, support product investment, and improve the company’s ability to scale its healthcare software operations.
Very Low Leverage And Positive Cash FlowExtremely low leverage limits refinancing pressure and preserves financial flexibility for product development, implementation capacity, or customer expansion. Positive free cash flow in 2025 and 2026 also provides evidence that recent earnings are converting into cash rather than relying solely on accounting profits.
Bears Say
Modest ProfitabilityDespite returning to profit, margins remain modest, leaving less protection if implementation costs rise or growth investment increases. Low operating profitability also limits the cash available for strategic initiatives and means stronger revenue growth may not translate proportionally into durable earnings improvement.
Volatile Historical ResultsThe sharp swing from sizable losses to recent profitability shows that earnings have not yet demonstrated a stable multi-year pattern. Such volatility makes underlying operating leverage less predictable and increases the importance of sustaining revenue growth while controlling delivery and operating costs.
Variable Cash ConversionRecent positive cash generation is encouraging, but the uneven historical record indicates that accounting earnings do not consistently convert into free cash flow. A renewed decline or negative cash period could reduce funding for expansion and make investment timing more dependent on operating performance.
Alcidion Group Limited News
ALC FAQ
What was Alcidion Group Limited’s price range in the past 12 months?
Alcidion Group Limited lowest share price was AU$0.08 and its highest was AU$0.14 in the past 12 months.
What is Alcidion Group Limited’s market cap?
Alcidion Group Limited’s market cap is AU$134.98M.
When is Alcidion Group Limited’s upcoming earnings report date?
Alcidion Group Limited’s upcoming earnings report date is Feb 25, 2027 which is in 162 days.
How were Alcidion Group Limited’s earnings last quarter?
Alcidion Group Limited released its earnings results on Aug 18, 2026. The company reported AU$0.001 earnings per share for the quarter, beating the consensus estimate of AU$0 by AU$0.001.
Is Alcidion Group Limited overvalued?
According to Wall Street analysts Alcidion Group Limited’s price is currently Undervalued.
Does Alcidion Group Limited pay dividends?
Alcidion Group Limited does not currently pay dividends.
What is Alcidion Group Limited’s EPS estimate?
Alcidion Group Limited’s EPS estimate is <0.01.
How many shares outstanding does Alcidion Group Limited have?
Alcidion Group Limited has 1,349,805,200 shares outstanding.
What happened to Alcidion Group Limited’s price movement after its last earnings report?
Alcidion Group Limited reported an EPS of AU$0.001 in its last earnings report, beating expectations of AU$0. Following the earnings report the stock price went up 4.598%.
Which hedge fund is a major shareholder of Alcidion Group Limited?
Currently, no hedge funds are holding shares in AU:ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcidion Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$0.15 (47.50% Upside)
AU$0.15 (47.50% Upside)
Blogger Sentiment
Bullish
AU:ALC Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth AU$30.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alcidion Group Limited
Alcidion Group Limited operates as a healthcare technology firm, specializing in the creation and licensing of software products across Australia, New Zealand, and the United Kingdom. Its flagship product, Miya Precision, is a consolidated platform built on the Fast Healthcare Interoperability Resources (FHIR) standard, aimed at enabling intelligent healthcare delivery. The company also supplies Smartpage, a mobile and web-based system designed to streamline hospital communications and task management for clinical and administrative personnel. Additional solutions include Patientrack, a tool for real-time patient monitoring and risk screening; Silverlink, which handles patient administration; and ExtraMed, software dedicated to optimizing clinical and patient flow. Furthermore, Alcidion provides a range of services encompassing product deployment, support and maintenance, systems integration, and data analysis. Founded in 2000 and headquartered in South Yarra, Australia, the company was formerly known as Alcidion Corporation Pty Ltd until its rebranding as Alcidion Group Limited in December 2015.
ALC Stock 12 Month Forecast
Average Price Target
AU$0.15
▲(47.50% Upside)
Technical Analysis
Oneview Healthcare Chess Depository Interests repr 1
―
Pro Medicus Limited
―
Mach7 Technologies
―
Beamtree Holdings Ltd
―
Artrya Limited
―